Teva Pharmaceutical Industries (TEVJF) Intangibles (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Intangibles across 18 years of filings, most recently posting $3.6 billion for Q1 2026.

• Quarterly Intangibles fell 13.85% year-over-year to $3.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 billion (down 13.85% YoY) and the FY2025 annual result came in at $3.8 billion, down 14.42% from the prior year.
• Intangibles eased to $3.6 billion in Q1 2026, from $3.8 billion in the prior quarter.
• Over five years, Intangibles peaked at $7.1 billion in Q1 2022 and troughed at $3.6 billion in Q1 2026.
• A 5-year average of $5.2 billion and a median of $5.1 billion in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2022 — Intangibles retreated 18.37% — and 2023, when it retreated 13.58%.
• Tracing TEVJF's Intangibles over 5 years: stood at $6.3 billion in 2022, then decreased by 14.08% to $5.4 billion in 2023, then retreated by 17.99% to $4.4 billion in 2024, then retreated by 14.42% to $3.8 billion in 2025, then declined by 4.55% to $3.6 billion in 2026.
• Business Quant data shows TEVJF's Intangibles at $3.6 billion in Q1 2026, $3.8 billion in Q4 2025, and $3.9 billion in Q3 2025.